Signal Transduction and Targeted Therapy

Article	Citations
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	1822
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1674
Dopamine as a teaching signal: understanding its role in shaping individual behavior	1482
Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly	1438
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	1330
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	1292
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	1271
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1269
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1191
Moving towards precision psychiatry: the hard nut of depression	1176
Chemo-photothermal synergy ignites antitumor immunity via ferroptosis	1134
Animal models for COVID-19: advances, gaps and perspectives	1102
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	1076
Sensory neurons: unveiling the symphony of wound healing	1065
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	1036
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	986
Identification of glutamine as a potential therapeutic target in dry eye disease	949
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	941
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	924
Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis	905
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	891
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	881
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	879
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	877
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	875

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	855
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	843
Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	843
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	817
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	805
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	780
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	778
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	778
Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2	773
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	764
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	754
Correction: The Hippo signalling pathway and its implications in human health and diseases	748
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets	736
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	730
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	725
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	722
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	717
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	701
Phototherapy in cancer treatment: strategies and challenges	676
Neutrophil extracellular traps in homeostasis and disease	673
Omicron spike protein: a clue for viral entry and immune evasion	635
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	632
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology	615
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	601
Top(ological-operon) secret behind the long-range transcriptional coupling	600
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	592
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	584
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	574
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	570
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	554
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	536
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	533
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	527
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer	519
Drugging the intrinsically disordered transactivation domain of androgen receptor	518
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	503
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	496
Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy	495
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)	485
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	483
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	479
Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism	478
Necroptosis triggers inflammatory interferon signatures in patient-derived metastatic breast cancer organoids	457
Dual epitope anti-LILRB4 synthetic T-cell receptor and antigen receptor (STAR)-T-cell therapy for relapsed/refractory acute myeloid leukemia	456
Beyond borders: the choroid plexus-immune communication during neuroinflammation	455
Platelets and diseases: signal transduction and advances in targeted therapy	452
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	451
Harnessing innate immune pathways for therapeutic advancement in cancer	446
The RING finger protein family in health and disease	437
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy	428

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	425
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	420
Mind-body control: a new perspective on motor neuron function	417
Base editing: a promising tool to rescue spinal muscular atrophy	414
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	411
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	407
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	403
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	401
Arterial inflammation after myocardial infarction: regulating the immune system	398
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	397
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	394
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	389
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	388
Nascent mRNA damage: depot and disposal	388
Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer	384
PD-1/LAG-3 signaling rewires T-cells via MYC inhibition	382
The cost of cure: cancer therapies sculpt somatic evolution and signaling landscapes in normal tissues	379
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates	378
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	377
Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia	375
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	373
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	364
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	353
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	339
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	337
Molecular insights of exercise therapy in disease prevention and treatment	335
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	334
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	333
Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosis	331
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	328
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	328
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	327
The consensus molecular subtypes of esophageal squamous cell carcinoma	327
Ring finger protein 213 regulates B-cell receptor signaling, metabolism, and development in B lymphocytes	325
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	319
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	311
Small molecules in the treatment of COVID-19	307
Mitochondrial heterogeneity in diseases	304
ENO2 drives tumor cell-induced M2 macrophage polarization to promote colorectal cancer liver metastasis	299
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	293
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	289
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	284
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	275
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	274
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	272
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	270
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	267
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	266
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	264
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	263
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	262
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	262
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies	255
Lactate metabolism in human health and disease	253
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	248
Single-cell genomics: the human biomolecular and cell atlases	246
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	244
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	242
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	236
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	234
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	234
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	233
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	231
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	229
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	227
Personalized pharmacokinetic–pharmacodynamic guided therapy via an induced pluripotent stem cell–derived multi-organoid platform in NF1-mutant breast cancer	227
Back to pluripotency: fully chemically induced reboot of human somatic cells	226
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	225
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	225
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	224
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels	221
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	221
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	221
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	219
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	217
Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial	216
Current landscape of innovative drug development and regulatory support in China	213
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	213
Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer	212
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	211

RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	211
CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia	208
Programmable synthetic receptors: the next-generation of cell and gene therapies	207
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function	206
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	205
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	204
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	202
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	201
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	200
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	199
Signaling pathways and targeted therapies for psoriasis	198
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	197
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	197
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	196
Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target	195
Universal scaling law: transcription factors homeostatically control promoter activity	192
BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis	192
Activated STING: an ion channel to trigger non-interferon-related functions	191
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	189
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	189
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	189
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	188
Bone morphogenetic protein signaling drives rete ridge morphogenesis: a distinct epidermal appendage program	187
Time’s up: mutation rate and lifespan	187
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	179
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	178
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	178
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	177
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	177
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	176
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	174
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	172
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	170
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	169
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation	169
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	167
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	167
Fever as thermal barrier: avian‑origin PB1 enables influenza A viruses to overcome mammalian febrile defense	167
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	167
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	166
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	165
The role of ER-associated degradation and ER-phagy in health and disease	162
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	162
Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming	162
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	160
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	159
Signaling pathways in obesity: mechanisms and therapeutic interventions	159
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	159
Targeted protein degradation: advances in drug discovery and clinical practice	158
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	156
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	156
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury	156
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	155
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	154
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	153
Redox regulation: mechanisms, biology and therapeutic targets in diseases	151
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	149
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	146
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	145
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	145
SLC7A11: a new regulator in diabetic wound healing	144
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	144
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	143
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	142
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	142
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	142
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread	141
PARP1-DNA co-condensation: the driver of broken DNA repair	141
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	140
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	139
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	138
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	137
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	136
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	135
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	134
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	134
Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth	134
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	134
A multicenter single-arm clinical study of Chinese children’s cancer group-acute promyelocytic leukemia-2017 (CCCG-APL-2017) protocol	133
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	133
Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial	131
SCGN deficiency is a risk factor for autism spectrum disorder	130
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	129
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)	129
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal c	127
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	126
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	123
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	123
Exosomes secreted from cardiomyocytes suppress the sensitivity of tumor ferroptosis in ischemic heart failure	121
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	119
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	119
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	118
Gut dysbiosis conveys psychological stress to activate LRP5/β-catenin pathway promoting cancer stemness	118
CAR-T cell therapy for cancer: current challenges and future directions	116
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	115